Skip to main content

Drug Interactions between Acova and Kcentra

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

argatroban prothrombin complex

Applies to: Acova (argatroban) and Kcentra (prothrombin complex)

CONTRAINDICATED: Since direct thrombin inhibitors are used for the treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT) and for anticoagulation in patients with or at risk for HIT, heparin-containing products such as prothrombin complex would not be indicated in these patients.

MANAGEMENT: Patients with known HIT should not receive prothrombin complex because it contains heparin. All formulations with heparin, including heparin lock flush, should be withdrawn prior to and during the treatment of heparin-induced thrombocytopenia. Clinicians should allow sufficient time for heparin's effect on the activated partial thromboplastin time (aPTT) to decrease prior to initiation of the thrombin inhibitor. Close clinical and laboratory observation for bleeding complications is recommended.

References

  1. (2013) "Product Information. Kcentra (prothrombin complex)." CSL Behring LLC

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer